Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000641314 | SCV000762955 | likely benign | Nemaline myopathy 2 | 2025-01-13 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV000641314 | SCV000896831 | uncertain significance | Nemaline myopathy 2 | 2018-10-31 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000839706 | SCV000981610 | likely benign | not provided | 2018-03-08 | criteria provided, single submitter | clinical testing | This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. |
Ambry Genetics | RCV002544663 | SCV003527100 | uncertain significance | Inborn genetic diseases | 2022-11-18 | criteria provided, single submitter | clinical testing | The c.15142C>A (p.Q5048K) alteration is located in exon 105 (coding exon 103) of the NEB gene. This alteration results from a C to A substitution at nucleotide position 15142, causing the glutamine (Q) at amino acid position 5048 to be replaced by a lysine (K). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Revvity Omics, |
RCV000839706 | SCV003811608 | uncertain significance | not provided | 2022-09-15 | criteria provided, single submitter | clinical testing |